The Evolution of Immune Checkpoint Inhibitor Combinations in Advanced Hepatocellular Carcinoma – A Systematic Review
Primary liver cancer is one of the most frequent causes of malignancy-related death globally, resulting in over 830,000 estimated deaths in 2020 [1]. It represents a continuously increasing health threat, with a 43% increase in deaths from this disease from 2000 to 2016 in the United States [2]. Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer, accounting for 75-85% of cases [3,4] and is unique in that it occurs largely in a background of chronic liver disease [5]. HCC is therefore associated with well-characterized risk factors including hepatitis B/C virus (HBV/HCV) infection, alcohol, diabetes, and other metabolic diseases [5,6].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Brandon M Meyers, Jennifer J Knox, David M Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C Tam, Howard J Lim Tags: Anti-tumour Treatment Source Type: research
More News: Alcoholism | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Endocrinology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Urology & Nephrology | USA Health